One, two, or three receptors
Semaglutide is a GLP-1 receptor agonist. Tirzepatide adds GIP to make a dual agonist. Retatrutide adds glucagon on top of that, making it a triple agonist. The receptor targets are the cleanest way to organize the class.
What the literature covers
Semaglutide and tirzepatide have large phase-3 clinical programs; retatrutide's human data is earlier-stage. Each product page states the study type and population for its cited research so the depth of evidence is never overstated.
Amylin as a companion mechanism
Cagrilintide, an amylin analog, is often studied alongside GLP-1 agonists rather than as a substitute, a different mechanism researched in combination.
